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Abstract
Background: microRNAs (miRNAs) are a group of non-coding single stranded RNAs measuring
approximately 22 nt in length that have been found to control cell growth, differentiation and
apoptosis. miRNAs negatively regulate their target genes and recently have been implicated in
tumourigenesis. Furthermore, miRNA expression profiling correlates with various cancers, with
these genes thought to act as both tumour suppressors and oncogenes. ret/PTC 1 is an oncogene
with constitutive kinase activity implicated in the development of papillary thyroid carcinoma
(PTC). This rearrangement leads to aberrant MAPK activation that is implicated in PTC
tumourigenesis.
Aim: The aim of this study was to identify the effect that ret/PTC 1 has on transcription and post-
transcriptional regulation in PTC by using DNA microarray and microRNA analysis.
Results: DNA microarray analysis revealed a group of genes differentially expressed between
normal thyroid cell lines and those harbouring a ret/PTC 1 rearrangement.
Furthermore, a unique miRNA expression signature differentiated between PTC cell lines with ret/
PTC 1 and a normal thyroid cell line. 21 miRNAs showed significant overexpression and 14 
miRNAs showed underexpression in these cell lines when compared to normal thyroid. Several of 
these up/down regulated miRNAs may be involved in PTC pathogenesis.
Background
In 1985, RET was first identified as a novel oncogene. RET
encodes a receptor tyrosine kinase, the ligands of which
belong to the glial cell line-derived neurotropic factor
(GDNF) family [1]. Chimeric RET oncogenes, designated
ret/PTC, display a ligand independent constitutive tyro-
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sine kinase activity and are implicated in the development
of papillary thyroid carcinoma (PTC). They are formed
from the juxtaposition of the genomic region coding for
the tyrosine kinase domain of RET with the 5'-promoter
regions of a variety of unrelated genes. At least 15 chimeric
mRNAs involving ten distinct donor genes have been
described. Of these, the most commonly occurring in PTC
are ret/PTC 1 [H4-(CCDC6)-RET] [2] and ret/PTC 3
[ELE1-RET] [3].
Papillary thyroid carcinoma is the most frequently occur-
ring type of thyroid malignancy accounting for approxi-
mately 80%–90% of cases. A unique feature of papillary
thyroid cancers is that oncogenes such as ret/PTC, activate
effectors that signal along the mitogen activated protein
kinase (MAPK) pathway playing important roles in the
pathogenesis of thyroid tumourogenesis. Genetic studies
suggest that ret/PTC activation is one of the key first steps
in thyroid cancer pathogenesis. The reported prevalence
of ret/PTC rearrangements in papillary carcinoma varies
from 3% to as high as 85% with the highest incidence in
radiation associated PTC. This variation reflects the differ-
ent sensitivities of the techniques used as well as geo-
graphic variations and the influence of environmental
factors such as ionizing radiation exposure [4,5]. Several
reports have shown that ret/PTC rearrangements are in
general associated with classic papillary architecture in
thyroid carcinoma and RET has been suggested to cause
structural and nuclear peculiarities of PTC. PTCs express-
ing ret/PTC tend to be small and do not exhibit a tendency
to progress to an aggressive phenotype [6-8]. However,
the exact role of ret/PTC in the context of papillary thyroid
carcinoma remains unclear and the complete repertoire of
genes and signalling pathways involved in pathogenesis
of thyroid disease remains poorly defined. A further short-
coming remains in the inadequacy of diagnostic and prog-
nostic markers with frequent reliance on conventional
morphological assessment.
Recently it has been proposed that microRNAs (miRNAs),
small non coding RNAs, may play a role in tumour forma-
tion including PTC development. Ambrose et al described
Lin-4 over a decade ago and there has been an explosion
of interest in the area since [9,10]. microRNAs are cleaved
from hairpin shaped precursors to yield mature miRNAs
of approximately 22 nucleotides in length. miRNAs nega-
tively regulate gene expression and function by targeting
mRNAs for cleavage or translational repression depending
on the degree of complementarity between the miRNA
and the target mRNA [11,12]. Because of their relatively
recent discovery, little is known about the exact processes
in which miRNAs function or the exact nature of their reg-
ulation. Studies on the regulatory roles of miRNAs in a
variety of organisms suggest that they have critical roles in
central biological processes and are regulators of in devel-
opment, cell proliferation, cell differentiation, stress
resistance, metabolism and apoptosis, all of which are
involved in tumourigenesis [13,14]. Not surprisingly as a
consequence aberrant regulation of miRNA expression
has been implicated in human disease including cancer.
Furthermore, a recent study showed that greater than 50%
of annotated human miRNAs are located in areas of the
genome known as fragile sites that are associated with
cancer [15]. This further supports a role for miRNAs in
cancer progression. Differential expression of miRNAs has
been shown between malignant and normal tissues of the
same tissue type and between different types of tumour.
This has lead to the hypothesis that tumours may each
have a discrete miRNA signature [16-18]. It has also been
reported that numerous oncogenes and tumour suppres-
sor genes are potentially regulated by miRNAs, or indeed
miRNAs may act as oncogenes or tumour suppressor
genes themselves. miRNA species may therefore be poten-
tially used as biomarkers for tumour diagnostics and treat-
ment.
Several groups have used a variety of techniques in order
to quantify miRNAs the most common including oligo-
nucleotide microarray technology, bead based flow cyto-
metric analysis, a modified invader assay and a new single
molecule technique. Each of these methods has distinct
advantages and disadvantages. Real-time PCR however,
has unparalleled sensitivity and specificity. It is also more
quantative than DNA microarray technology which is the
preferred method in recent publications. The TaqMan®
microRNA RT-PCR method used in this study is a new real
time quantification method to accurately detect mature
miRNAs. The stem-loop structure of the primers is specific
to the 3' end of the mature miRNA and creates a steric hin-
drance to prevent priming of the precursor miRNA. The
aim of this study was to identify the effect the ret/PTC 1
oncogene has on transcription and post-transcriptional
regulation in tumourigenesis by using a combination of
DNA microarray and microRNA analysis.
Results
Differential gene expression using DNA Microarrays
Upregulated genes
In order to investigate differential gene expression in pap-
illary thyroid carcinoma cell lines, a comparison was
made between the two cell lines harbouring ret/PTC 1
rearrangement [Nthy-ori transfected with ret/PTC 1 and
TPC-1] and normal thyroid cell lines. To identify potential
markers of malignancy t-test with FDR correction (<0.1)
were used to compare the two groups [19]. A p-value cut
off of < 0.01 and a fold change difference of >2 resulted in
a list of 47 genes (Table 1).Molecular Cancer 2006, 5:70 http://www.molecular-cancer.com/content/5/1/70
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Downregulated genes
Similar cut off criteria were applied in analysing downreg-
ulated mRNA species. 29 genes were found to be statisti-
cally significant, see Table 2. Hierarchical clustering was
performed based on statistically different genes (Fig. 1).
Differential miRNA expression using TaqMan® microRNA 
assays
Upregulated
miRNAs were considered to be significantly upregulated
when there was a fold change of > 2 fold in PTC cell lines
Table 1: Upregulated Genes in ret/PTC 1 cell lines v N-thy-ori
GENE SYMBOL GENE NAME
PLSCR4 phospholipid scramblase 4
Unassigned Unassigned
Unassigned Unassigned
TXNIP thioredoxin interacting protein
IFI44 interferon-induced protein 44
PACS2 phosphofurin acidic cluster sorting protein 2
TBCIDI TBC1 domain family, member 1
HLA-A major histocompatibility complex, class I, A
PLSCR2 phospholipid scramblase 2
Unassigned Unassigned
SBLF stoned B-like factor
PCAF p300/CBP-associated factor
C20orf128 Chromosome 20 open reading frame 128
MGC17403 hypothetical protein MGC17403
MCPH1 microcephaly, primary autosomal recessive 1
Unassigned Unassigned
SH3BP1 SH3-domain binding protein 1
STXBP2 syntaxin binding protein 2
CAMLG calcium modulating ligand
IFITM3 interferon induced transmembrane protein 3 (1-8U)
FRS3 fibroblast growth factor receptor substrate 3
SEMA3F sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 
(semaphorin) 3F
TRIM28 tripartite motif-containing 28
CYP2D6 cytochrome P450, family 2, subfamily D, polypeptide 6
HLA-C major histocompatibility complex, class I, C
TMED6 transmembrane emp24 protein transport domain containing 6
CCNG1 cyclin G1
KLF10 Kruppel-like factor 10
RPL15 Ribosomal protein L15
PNPLA2 patatin-like phospholipase domain containing 2
CEBPB CCAAT/enhancer binding protein (C/EBP), beta
HTRA1 HtrA serine peptidase 1
HLA-A major histocompatibility complex, class I, A
ZNF329 zinc finger protein 329
C20orf29 G protein-coupled receptor, family C, group 5, member C
ARSA arylsulfatase A
FAM100B family with sequence similarity 100, member
C4orf14 chromosome 4 open reading frame 14
Membralin Membralin
C1orf164 Chromosome 1 open reading frame 164
RPL32 Ribosomal protein L32
Unassigned Unassigned
YHWAE tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, epsilon polypeptide
PAFAHIB platelet-activating factor acetylhydrolase, isoform Ib, alpha subunit 45 
kDa
GPRC5C G protein-coupled receptor, family C, group 5, member C
C10orf104 Chromosome 10 open reading frame 104
47 upregulated genes between ret/PTC 1 cell lines and normal.Molecular Cancer 2006, 5:70 http://www.molecular-cancer.com/content/5/1/70
Page 4 of 12
(page number not for citation purposes)
compared with the normal cell line N-thy-ori. miRNAs
upregulated in both ret/PTC1 containing cell lines are
listed in table 3, (21 in total). Four of these upregulated
miRNAs showed significantly higher fold change than the
other upregulated miRNAs, these are mir-128a [Fold
Change (FC) = 42 (Nthyori-ret)/45 (TPC-1)], mir-128b
[FC = 55/10], miR 139 [13/14] and mir-200a [25/5874].
(Table 3, Fig 2 and Fig 3).
Downregulated
Similar criteria were used to determine miRNAs signifi-
cantly under-expressed in ret/PTC 1 containing cell lines
compared with N-thy-ori. A total of 14 miRNA species
were identified in this cohort. Again four miRNAs showed
significantly more underexpression compared to the other
downregulated miRNAs. These miRNAs are mir- 154* [FC
= 14/12], mir-181a [FC = 5/3401] and mir-302b [FC = 5/
10] and mir302c [FC = 5/6]. (Table 3, Fig 2 and Fig 3)
mRNA (transcription) and miRNA (regulation) expression 
correlation
miRNAs interact and regulate their target genes by cleav-
age or translational inhibition.
The current challenge is to identify biologically relevant
targets that are regulated by individual miRNAs. Further
complicating this task is the fact that every miRNA can
potentially bind and regulate many mRNA targets and
each mRNA can be bound and regulated by several miR-
NAs. miRNAs usually bind to their targets with incom-
plete complimentarity within the 3' untranslated region
(UTR) of the mRNA target. Because of this the identifica-
tion of targets is impossible with a simple BLAST search.
Most bioinformatic methods use the first 2–8 bases of the
mature miRNA sequence to search for complementarity to
the 3' UTR of all expressed genes. This will yield a list of
genes with diverse functions that a single miRNA can bind
to. There are three publicly available databases for predic-
tion of miRNA targets. These are miRBase [20], PICTAR
[21], and TARGETSCAN [22]. For example, all animal
miRNA sequences from the miRBase Sequence database
are scanned against 3'-UTRs predicted from all available
species in Ensembl along with Caenorhabditis briggsae and
Drosophila pseudoobscura. P-values are assigned to individ-
ual miRNA-target binding sites, multiple sites in a single
UTR, and sites that appear to be conserved in multiple
species. The interface connects each miRNA to a list of pre-
Table 2: Downregulated Genes in ret/PTC 1 cell lines Vs normal.
GENE SYMBOL GENE NAME
POMT2 ring finger protein 126
RNASEN ribonuclease III, nuclear
PSMD2 proteasome (prosome, macropain) 26S subunit, non-ATPase, 2
CSRP1 cysteine and glycine-rich protein 1
DCTN5 dynactin 5 (p25)
ARL4A ADP-ribosylation factor-like 4A
TXNRD1 thioredoxin reductase 1
Keratin type1 Keratin Type1 cytoskeletal
PSMC1 proteasome 26S subunit, ATPase, 1
TPM3 tropomyosin 3
BIT1 Bcl-2 inhibitor of transcription
TPM3 Tropomyosin 1
RAB32 RAB32, member RAS oncogene family
C16orf35 Chromosome 16 open reading frame 35
C21orf70 Chromosome 21 open reading frame 70
ITK IL2-inducible T-cell kinase
TFRC transferrin receptor (p90, CD71)
HISTIH4L histone 1, H4l
TPM1 tropomyosin 1 (alpha)
Unassigned Unassigned
KRT 18 Keratin 18
KIAA0256 KIAA0256 gene product
RNF126 thioredoxin reductase 1
FLJ37549 proteasome (prosome, macropain) 26S subunit, non-ATPase, 2
Unassigned unassigned;unassigned
Unassigned protein-O-mannosyltransferase 2
Unassigned unassigned;unassigned
FGFBP1 fibroblast growth factor binding protein 1
NPM1 nucleophosmin (nucleolar phosphoprotein B23, numatrin)
Unassigned Unassigned
29 downregulated genes between the ret/PTC 1 cell lines and normalMolecular Cancer 2006, 5:70 http://www.molecular-cancer.com/content/5/1/70
Page 5 of 12
(page number not for citation purposes)
dicted gene targets. Comparing the lists of the miRNA tar-
gets and differentially expressed genes, 15 differentially
expressed genes from Table 1 and 2 were in the list of pre-
dicted targets for miRNAs from Table 3. This is illustrated
in Table 5. Thus, there was correlation between the data
sets obtained from the functional expression (microarray)
and the regulatory (miRNA) data sets.
Discussion
The primary aim of this study was to try to elucidate the
effects of the RET proto-oncogene on gene expression and
transcriptional regulation in a matrix of cells lines har-
bouring ret/PTC 1 rearrangement. This was performed
using Applied Biosystems whole genome expression array
technology and TaqMan® microRNA assays. The sequenc-
ing of the human genome and advances in microarray
technology has significantly increased understanding of
the molecular pathogenesis of thyroid tumour formation
in recent years. On order to gain a better understanding of
the genes and pathways involved in PTC and unveil
potential biomarkers, several groups have applied DNA
microarray technology to show the genetic profiles in PTC
[23-26]. These profiles uncovered genes that were sug-
gested to be involved in processes such cell adhesion and
cell structure, inhibition and induction of apoptosis, cell
proliferation and differentiation.
This study showed a group of differentially expressed
genes in two cell lines contingent on a rearrangement of
the  RET  oncogene when compared to normal thyroid.
Among the genes found to be over-expressed, those
involved in biological processes such as cell differentia-
tion and proliferation were over-represented. Such genes
included CEBPB, CCNG1, IFITM3 and HTRA1. CEBPB is
a bZip transcription factor that cooperates with Stat 6 to
activate transcription [27]. It has been shown to have a
critical role in Ras mediated tumourigenesis and cell sur-
vival and has been implicated as a target for tumour inhi-
bition. Studies have shown that it is expressed in the
cytoplasm of PTC and is implicated to play a role in the
regulation of thyroid specific genes and processes and has
altered function in thyroid carcinoma [28]. It is involved
in the positive regulation of genes involved in the
immune and inflammatory response, a group which has
been shown to be associated with ret/PTC 1 and tumour
formation in this study and in previous thyroid literature
Hierarchical clustering of ret/PTC 1 cell linesand N-thy-ori cell line based on the gene lists obtained from treatment compari- son analysis Figure 1
Hierarchical clustering of ret/PTC 1 cell linesand N-thy-ori cell line based on the gene lists obtained from 
treatment comparison analysis. The column dendrogram clearly shows cases clustering on the basis of RET rearrange-
ment. To the left are the normal thyroid cell lines with no RET rearrangement and to the right are the cell lines with ret/PTC 
1 rearrangement. Red denotes genes with relative increased expression and green denotes genes with relative decreased 
expression.
 Molecular Cancer 2006, 5:70 http://www.molecular-cancer.com/content/5/1/70
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[29]. CEBPB also has been shown to be a regulator of Cox-
2; Cox-2 has recently been implicated as a potential
biomarker in thyroid neoplasm [30].
HTRA1 [31] is a member of the trypsin family of serine
proteases and is a regulator of cell growth. It has been
implicated in the pathology of several diseases. Several
papers have implicated matrix metalloproteases in PTC
tumour progression; during tumour invasion they
degrade protein components of the extracellular matrix
aiding angiogenesis [32]. HTRA has been proven to cause
the induction of matrix metalloproteases 1 and 3.
Cell signalling also showed an increase in ret/PTC 1 cell
lines, SEMA3F is a protein involved in signalling. Endog-
enous SEMA3F causes cells to round and loose extracellu-
lar contacts a process which may contribute to the classic
appearance of PTC. Membralin (C19orf6) is a novel gene
originally cloned from a human ovarian cancer cell line. It
is suggested to be a tumour associated marker in ovarian
and colorectal cancer [33,34]. It was also shown to be
over-expressed in ret/PTC 1 cell lines when compared to
normal. It is interesting to hypothesize that there may be
a link between membralin overexpression and the papil-
lary architecture seen in PTC and in ovarian cancers.
Furthermore, genes involved in p53 pathway were over-
represented. P300/CBP- associated factor (PCAF) was one
such gene and is a co- activator of the tumour suppressor
p53. PCAF was found to be induced by p53 in breast can-
cer cell lines and indirectly regulated ERK1 effecting cellu-
lar proliferation [35].
Among the genes shown to be down-regulated in ret/PTC
1 cell lines when compared to normal, those involved in
cell structure and motility were over-represented. Exam-
ples of such genes include DCTN5, TPM1, TPM3, CRP1
and Keratin type 1. Tumour cells are held together by
direct cell – cell contact and by adhesion to the extracellu-
lar matrix. Loss of adhesion is thought to promote tumour
invasiveness and increase the metastatic potential of carci-
noma. Loss of these cell structure genes might also be
involved in the papillary pattern of PTC. Tropomysoin
(TM) has a role in regulating cellular functions associated
with cytoskeletal remodelling. Suppression of TMs is a
prominent feature of many transformed cells. TM1 expres-
sion is abolished in human breast cancer cell lines and
also in the ret/PTC 1 cell lines in this study. This downreg-
ulation may destabilize microfilament architecture and
facilitate survival of neoplastic cells and promote malig-
nant growth [36]. PSMD2 (TRAP2) participates in TNF
signalling pathway and was found to be downregulated.
This suggested a role for PSMD2 in cell survival. Rab32
inactivation may represent a component of the oncogenic
pathway of microsatellite-unstable gastrointestinal aden-
ocarcinoma. It encodes an A-kinase anchoring protein
and is often hypermethylated in gastric and colon cancers
and was found to also be downregulated in PTC cell lines.
Rab32 has also been shown to induce apoptosis [37,38].
Of particular interest in this study was the discovery of the
underexpression of DROSHA in PTC cell lines. This is the
core nuclease that executes the initiation step of miRNA
processing in the nucleus. DROSHA collaborates with
Dicer in stepwise processing of miRNAs and has a key role
in miRNA mediated gene regulation processes such as
development and differentiation [39]. Components of the
miRNA-machinery have been implicated in tumourigene-
sis and reduced levels have been shown to be associated
with cancer [40]. Its differential expression may effect the
expression of certain miRNAs such as those in table 3 and
consequently play a role in gene expression regulation.
This data corroborates the importance of these pathways
in PTC. The genes involved may play a role in tumour ini-
tiation and in the morphological characteristic of classic
PTC due to the ret/PTC 1 oncogene. Several reports have
shown that ret/PTC 1 rearrangements are in general asso-
ciated with classic papillary architecture in thyroid carci-
noma. The profiles examined contained genes that were
suggested to be involved in processes such as cell adhe-
sion and cell structure, such as tropomysoins, and inhibi-
tion and induction of apoptosis. This aberrant expression
has an impact on the molecular structure and the extracel-
lular matrix which may facilitate destabilization of the
Table 3: miRNA expression in ret/PTC 1 harbouring Cell lines Vs 
normal cell lines
Upregulated Downregulated
mir-34a mir-15a
mir-96 mir-34c
mir-99a mir-107
mir-100 mir-127
mir-125b mir-135b
mir-128a mir-145
mir-128b mir-149
mir-130b mir-154*
mir-139 mir-181a
mir-141 mir-218
mir-142-3p mir-299
mir-146 mir-302b
mir-148 mir-302c
mir-185 mir-323
mir-200a mir-370
mir-200b
mir-211
mir-213
mir-216
Let-7dMolecular Cancer 2006, 5:70 http://www.molecular-cancer.com/content/5/1/70
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microfilament architecture. While also adding to tumour
spread this phenomenon may contribute to the classic
papillary appearance associated with this rearrangement.
Gene expression has recently been shown to be regulated
by small noncoding RNAs called microRNAs (miRNAs). It
is believed that miRNAs are responsible for fine tuning
gene expression and are thought to regulate approxi-
mately 30% of the human genome, making them one of
the largest classes of gene regulator. Several clues have
pointed to the potential role of miRNAs in cancer and sug-
gest that aberrations in miRNA expression may be impor-
tant in tumour progression by regulating genes and
pathways involved in cancer associated processes. Studies
have reported that reduced levels of the Let-7 family of
miRNAs have an association with lung cancer tumouri-
genesis [41,42]. The miRNA cluster of miR-17- miR-92 is
highly expressed in many B-cell chronic lymphomas [43].
Furthermore, Mir 15a-Mir 16 expression is upregulated in
B-cell chronic lymphoma and leukaemia and falls within
a region thought to harbour a tumour suppressor gene.
Glioblastomas and breast tumours have also been
reported to show over expression of miR-21 [44,45].
This study examined, by real-time PCR, the expression of
miRNA in papillary thyroid carcinoma cell lines with ret/
PTC1 rearrangement.
Tables 3 shows a set of differentially expressed miRNAs in
2 cell lines with ret/PTC1 rearrangement when compared
to normal thyroid cell line. 21 miRNAs were found to be
overexpressed and 14 miRNAs were underexpressed in
both cell lines when compared to Nthy-ori 3-1. These
miRNAs are effected by direct ret/PTC 1 expression or by
the expression of other genes that are induced by ret/PTC
1 such as transcription factors. Little is known about the
function of these miRNAs and only a subset has been
found to be differentially expressed in other cancers. Of
the miRNAs in table 3, miR-181a expression was down-
regulated and expression of miR-200b and miR-141 was
up-regulated. Ciafre et al found miR-181a expression to
be downregulated in glioblastoma [45]. Studies have
reported that miR-181 upregulated during differentiation
and suggest that miR-181 downregulates the homeobox
protein Hox-A11 (a repressor of the differentiation proc-
ess), thus establishing a functional link between miR-181
and the complex process of differentiation. In fully differ-
Fold Change of miRNAs in ret/PTC harbouring cell lines Vs Normal Figure 2
Fold Change of miRNAs in ret/PTC harbouring cell lines Vs Normal. Delta delta CT was performed using Nthy-ori 
3-1 as a normal control. The log of the RQ values was used to plot the relative fold change of Nthy-Ret1 and TPC-1 against 
Nthy-ori 3-1. miRNAs are on the x axis.
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entiated tissue miR-181 was found to be downregulated,
PTCs are well-differentiated carcinomas therefore this
may explain downregulation of miR-181a in this study.
miR-200b and miR-141 have also been shown to be
highly overexpressed in malignant cholangiocytes and in
colon carcinoma [46,47]. Studies showed that their inhi-
bition increased sensitivity to the anticancer drug gemcit-
abine and also decreased cell growth suggesting a role for
their involvement in tumour formation.
An immediate obstacle facing research groups at present is
the lack of confirmed miRNA gene targets. Although mul-
tiple approaches have been suggested from bioinformat-
Table 4: Predicted targets for differentially expressed miRNAs
miR-128a VEGFC, CDK9, RAB20, ST14, THRAP1, TXNIP, TRAF1, LGALs3, PTPN6, SLC6A7, ADAMTS6, ITGA3, RAB27A RAB34, ILI9, Elf3S4, GDF15, CASP8, 
CDKN2A, DUSPSP, HTRA 2, HLA-G, CDH 4, PCDH3, IFITM1, TBC1D2, SERPINA3 CASP10, ZNF432, NEK2, MAP3K1IPI, CDH24
miR-128b PLK2, PRKD1, ADORA2B, ZNF385, CASC3, PAIP2, ITGB4BP CRKL, CDH24, ING5, BAG2, EGFR, ST14, THRAP1 CORO1CE2F, E2F3, PDGFRA, INSR, 
CITED2, STX16
miR-139 JUN, GAS2, MYST3, PTPRF, TGIF, XPO4, GDF10, MAP2, PCDH10
miR-181a TMED4, TGFB1, PRKCD, MLK1, MAP3K10, WTAP, TSGA10 FOS, TUPBP1, VCAM, DROSHA, IRS2, TNFAIP1, RASSF1, ILISR1, DDIT4, PLAG1, GPBP1, 
PRR6, APIP, CKSIB IL2, FGFR2, RAP1B
miR-370 RAB3IP, PTPRG, CCN5, VSP6, CCL21, CNTNAP1, LTBP1 MAP3K8, GFRA2, MMP16, CCNK, ETV6, FGF7, THRAP2 BRCA1, FOSB
miR-302c RAB43, CELSR3, NOTCH1, MET, CALCR, NOTCH2, THRAP2, TPO52, DAAMI, PDGFRA, MAD1A
Upregulated miRNAs in ret/PTC 1 cell lines = miR-128a, miR-128b, miR139
Downregulated miRNAs in ret/PTC 1 cell lines = miR-181a, miR-370, miR-302c
Heat map of miRNA expression Figure 3
Heat map of miRNA expression. miRNA expression. Each miRNA listed was detected as significantly differentially 
expressed between ret/PTC 1 cell lines and N-thy-ori. The delta CT values for each miRNA were used to create the heat map.
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ics including many prediction algorithms accurate target
prediction and validation are still major obstacles facing
miRNA researchers. Each miRNA found to be significantly
up/down regulated from table 3 was imputed into the
algorithms, miRBase, PICTAR and TARGETSCAN to
search for potential miRNA:miRNA target pairings. The
potential binding partners of 6 of these miRNAs are listed
in table 4. It is interesting to note that these differentially
expressed miRNAs potentially bind and regulate a
number of genes that have implications in thyroid carci-
noma progression such as genes involved in thyroid func-
tion, MAPKKK cascade, retinoic acid receptors, cell
adhesion and cell structure associated genes, genes
involved in cell signalling, G-protein mediated signalling,
oncogenesis and cell cycle control. Examples of these
genes include thyroid hormone interacting protein, proto-
cadherin, MAP3K10, KIT, PDGFRA and exportin 4. There-
fore, it seems plausible that this subset of miRNAs may be
important in the progression of thyroid carcinoma by reg-
ulating genes involved in thyroid neoplasia such as those
found in this study discussed above.
Analysis of DNA microarray data showed a group of genes
that are differentially expressed in ret/PTC1 harbouring
cell lines (Table 1 and 2). Comparing this list of genes
with the list of putative miRNA targets yielded from anal-
ysis using PICTAR, TARGETSCAN and miRBase showed
that 15 of the differentially expressed genes are targeted by
several miRNAs that are significantly up/downregulated
in cell lines with ret/PTC 1 rearrangement. This data is
shown in Table 5. Again it is interesting to speculate that
these genes are regulated by their corresponding miRNA
thereby contributing to tumour development in thyroid.
It remains difficult to identify the precise target mRNA of
each miRNA species. Therefore without further experi-
mental investigation any mRNA:miRNA partners are
essentially speculative and selection involves a degree of
subjectivity.
Recent studies on miRNA deregulation in PTC found an
aberrant miRNA expression profile in PTCs compared to
normal thyroid tissues. In particular, a significant increase
in miR- 222, miR-221, miR-146 and miR-181b was seen
[48,49]. In this study miR-146 was upregulated 500 fold
in TPC-1 cell line only. It is possible this miRNA may play
a role in a late stages of tumour formation and progres-
sion; given the transfected cell line had only been exposed
to ret/PTC1 for a short period (3 passages). Alternatively,
the difference may reflect the accumulation of several
genetic insults. The other miRNAs [miR-222, miR- 221,
miR-181b], however, were not found to be upregulated
significantly. This may be due to the differences in experi-
mental approaches; de la Chapelle et al and Fusco A et al
used miRNA microarrays. They also used different chem-
istry and fresh tissue samples; also the RET status of each
PTC case was not disclosed.
This field of miRNA research is young and many impor-
tant questions still remain. It is clear that miRNAs exert a
regulatory role on protein coding genes in a variety of spe-
cies and their deregulation may contribute to the develop-
ment of human disease. However, the precise biological
function of miRNAs has yet to be fully elucidated.
Even without more in-depth knowledge of their exact
function or role in PTC, it seems reasonable that a distinct
signature of miRNAs or miRNA expression profiles
assigned for thyroid tumours might be used as an adjunct
in diagnosis and prognostication of thyroid neoplasia. It
has been suggested that miRNA signatures may be more
effective than profiles of protein coding genes in distin-
guishing tumours from benign lesions. Fortunately miR-
Table 5: miRNAs and Predicted Targets.
Up-regulated Genes Potential Binding Partner (down-regulated)
IFI44 Mir-299
TXNIP Mir-302c, mir-302b
CCNG1 Mir-181a
TRIM4 Mir-181a
HTRA1 Mir-302b, mir-302c
PNPLA2 Mir-181a, mir-34c
YWHAE Mir-15a
CYP2D6 Mir-370
ZNF329 Mir-181a
Down-regulated Genes Potential Binding Partner (up-regulated)
TPM1 Mir-181a, mir-185, mir-128b, mir-96, mir-128a
NPM1 Mir-200b
RAB32 Let-7d
FGFBP1 Mir-99a, mir-100
DROSHA Mir-200bMolecular Cancer 2006, 5:70 http://www.molecular-cancer.com/content/5/1/70
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NAs, unlike mRNA targets remain intact in routinely
collected paraffin embedded samples, a fact which
increases their potential use as clinical biomarkers. miR-
NAs also have the potential as possible treatment targets.
One example of potential miRNA targeted therapy has
been shown with miR-127 in bladder cancer. This sug-
gests the possibility of direct targeting of miRNAs that are
amplified or upregulated in patient tumours.
Conclusion
This study is an in vitro model for the biological and regu-
latory processes that occur in human thyroid diseases due
to ret/PTC1 rearrangement. As miRNAs are stable, abun-
dant and easily detectable they represent ideal candidates
for effective diagnostic biomarkers. Future exploration on
a larger cohort of samples will hopefully determine the
correlation between these miRNAs and their host genes in
PTC and help aid in the identification of miRNA biomar-
kers.
Methods
Cell culture and transfection
Nthy-ori 3-1 (ECACC, Wiltshire, UK) is a normal thyroid
follicular epithelial cell line.
The cell line is derived from normal thyroid tissue of an
adult that has been transfected with a plasmid encoding
for the SV40 large T gene.
TPC-1 is a cell line derived from a papillary thyroid carci-
noma. This cell line expresses the ret/PTC-1 oncogene.
Both cell lines were grown to confluence in a humidified
atmosphere containing 5% CO2 at 37°C in the following
plating medium: RPMI 1640 with 2 mM L-glutamine,
10% Foetal calf serum (FCS), Penicillin (100 U/ml) and
Streptomycin (100 μg/ml). ret/PTC 1 transcript was
cloned into the multiple cloning site of pcDNA4/TO using
standard molecular techniques involving restriction and
ligation. This is part of the TREx tetracycline-regulated
mammalian expression system (Invitrogen, UK). Expres-
sion of the gene of interest from pcDNA4/TO is controlled
by the CMV promoter (into which 2 copies of the tet oper-
ator 2 (TetO2) sequence have been inserted in tandem.)
Each TetO2 sequence serves as a binding site for 2 mole-
cules of the Tet repressor. The second major component of
the T-REx system is the pcDNA6/TR© regulatory vector
which expresses high levels of the TetR gene under the
control of the human CMV promoter. In the absence of
tetracycline, the Tet repressor forms a homodimer that
binds with high affinity to each TetO2 sequence in the
promoter of the inducible expression vector. Upon addi-
tion, tetracycline binds with high affinity to each Tet
repressor homodimer and causes a conformational
change in the repressor that renders it unable to bind to
the Tet operator. The Tet repressor:tetracycline complex
then dissociates from the Tet operator and allows induc-
tion of transcription from the gene of interest. pcDNA6/
TR and pcDNA4/TO-ret/ptc1 were tranfected into N-thy-
ori cells using Genejuice™ transfection agent (Novagen,
Germany) using the recommended protocol and grown in
the presence selection agents, Blasticidin (Sigma Aldrich)
and Zeocin (Sigma Aldrich) to yield pure cultures.
Nucleic acid extraction
Following trypsinisation of cultured cells, cell pellets (3–
4 × 106 cells) were collected and RNA was extracted using
RNeasy® mini kit (Qiagen Ltd., West Sussex, UK). See Fig-
ure 1. RNA quantity and quality are assessed using the
NanoDrop® ND-1000 Spectrophotometer (Wilmington,
USA) and the RNA 6000 Nano LabChip® Kit in conjunc-
tion with the Agilent 2100 Bioanalyser (Agilent technolo-
gies, Waldbronn, Germany). Taqman® RT-PCR was used
for Ret/PTC1 rearrangement detection. Primers and
probes used in this experiment were designed and used
according to the Applied Biosystems (Foster City, CA,
USA) Assays-by-Design SM service. Amplification and
analysis was performed on an ABI Prism 7000 Sequence
Detection System (Applied Biosystems, CA, USA) (48°C
for 30 min then 92°C for 15 sec, 60°C for 1 min × 40
cycles).
Microarray analysis
The Applied Biosystems 1700 Expression Array System is
based on a microarray design that represents the whole
human genome. The V.2 array has 32,878 60-mer oligo-
nucleotide probes for the interrogation of 29,098 individ-
ual human genes and more than 1,000 control probes. V2
arrays were used to analyse the transcriptional profiles of
the cell line RNA samples in this study. Digoxigenin-UTP
labeled cRNA was generated and linearly amplified from
2 μg of total RNA using Applied Biosystems Chemilumi-
nescent RT-IVT Labelling Kit v 2.0 following the manufac-
turer's protocol. Array hybridization, chemiluminescence
detection, image acquisition and analysis were performed
using Applied Biosystems Chemiluminescence Detection
Kit and 1700 Chemiluminescent Mircoarray Analyzer fol-
lowing manufacturer's guidelines. Each microarray was
initially pre-hybridised at 55°C for 1 hr in hybridization
buffer with blocking reagent. 10 μg of labeled cRNA tar-
gets were fragemented by incubating with fragmentation
buffer at 60°C for 30 min, mixed with internal control tar-
get (ICT, 24-mer oligo labeled with LIZ fluorescent dye)
and hybridized to each pre-hybed microarray in a 1.5 ml
volume at 55°C for 16 hr. After hybridization, the arrays
were washed with hybridization wash buffer and chemi-
luminscence rinse buffer. Enhanced chemiluminescenct
signals were generated by incubating arrays with anti-dig-
oxigenin alkaline phosphatase, enhanced with Chemilu-
minescence Enhancing Solution and finally by addingMolecular Cancer 2006, 5:70 http://www.molecular-cancer.com/content/5/1/70
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Chemiluminescence Substrate. Images were collected for
each microarray using the 1700 analyser. Images were
autogridded and the chemiluminescent signals were
quantified, corrected for background and spot and spa-
tially normalized. Replicates were performed.
Statistical analysis
Microarrays were analysed using R version 1.9.1 [a free
language and environment for statistical analysis and
graphics] (R Development Core Team, 2004). Arrays were
normalised using Quantile normalisation. The primary
means of identifying genes that were differentially
expressed between groups was based on fold change and
statistical significance. An ANOVA test was used to gener-
ate p-values for statistical difference between groups. P-
values were then adjusted for multiple comparisons using
a technique described by Benjamini and Hochberg with a
cut of FDR <0.1 [19]. Genes were deemed statistically dif-
ferent between groups fold change >2 fold. Hierarchical
clustering was performed based on statistically different
genes (Fig. 1). Gene ontology analysis was performed
using an online database known as PANTHER (pan-
ther.appliedbiosystems.com). Its functions include the
ability to merge and differentiate genes within lists and
the ability to check for over-representation of genes with a
particular biological function, or involved in a specific
biological pathway.
miRNA analysis
Applied Biosystems TaqMan® microRNA (miRNA) assays
are designed to detect and quantify mature miRNAs using
a looped-primer real time PCR. The human early access
panel used in this study contained 160 individual assays
covering many of the identified human miRNAs. The
assay involved 2 steps: Step one; a Stem-looped RT, and
Step two; a Real Time PCR. Briefly, single stranded cDNA
was generated from total RNA sample by reverse transcrip-
tion using the Applied Biosystems High-Capacity cDNA
Archive Kit (Applied Biosystems, CA, USA) following
manufacturer's protocol. RT reactions contained 10 ng of
total RNA, 50 nM stem-looped RT primer, 1 × RT buffer,
0.25 mM each of dNTPs, 3.33 U/Ol Multiscribe reverse
transcriptase and 0.25 U/Ol RNase Inhibitor. PCR ampli-
fication was carried out using sequence specific primers
on the Applied Biosystems 7900 HT Fast Real-Time PCR
system. The reactions were incubated in a 96-well optical
plate at 95°C for 10 min, following by 40 cycles of 95°C
for 15s and 60°C for 10 min. Analysis of relative miRNA
expression data was performed using ΔΔCT method with
hsa-let-7a as an endogenous control. Two negative con-
trols were also used, ath-mir159a and cel-lin-4.
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